Skip to main content
Article thumbnail
Location of Repository

Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

By David Preiss, Sofia Zetterstrand, John J.V. McMurray, Jan Östergren, Eric L. Michelson, Christopher B. Granger, Salim Yusuf, Karl Swedberg, Marc A. Pfeffer, Hertzel C. Gerstein and Naveed Sattar
Topics: Original Research
Publisher: American Diabetes Association
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2006). A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed.
    2. A new look at screening and diagnosing diabetes mellitus.
    3. (1997). Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. Diabetes Metab
    4. (2000). Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev
    5. Diabetes, left ventricular systolic dysfunction, and chronic heart failure.
    6. Effects of candesartan in patients with chronic heart failure and preserved leftventricularejectionfraction:theCHARMPreserved Trial.
    7. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    8. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    9. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
    10. (2004). Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes
    11. ElliottWJ,MeyerPM.Incidentdiabetesin clinical trials of anti hypertensive drugs: a network meta-analysis.
    12. et al.Effectsofcandesartanonmortalityand morbidity in patients with chronic heart failure: the CHARM-Overall programme.
    13. (1994). et al.Glycatedhemoglobinpredictsprogression to diabetes-mellitus in Pima-Indians with impaired glucose-tolerance. Diabetologia
    14. et al.ThehemoglobinA1clevelasaprogressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure.
    15. Functional class in patients with heart failureisassociatedwiththedevelopment ofdiabetes.AmJMed2003;114:271–275
    16. (2007). Glucoselevelspredicthospitalizationforcongestive heart failure in patients at high cardiovascular risk. Circulation
    17. Hemoglobin a1c predicts diabetes but not cardiovascular disease in nondiabetic women.
    18. (2008). Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J
    19. (2009). Liver enzymesasapredictorforincidentdiabetes in a Japanese population: the Hisayama study.
    20. (2008). Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond)
    21. (2007). Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev
    22. (2001). Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res
    23. Statins and newly diagnosed diabetes.
    24. The incidence of congestive heart failure intype2diabetes.DiabetesCare2004;27:

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.